Design Therapeutics, Inc. Profile Avatar - Palmy Investing

Design Therapeutics, Inc.

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia…

Biotechnology
US, Carlsbad [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of DSGN's Analysis
CIK: 1807120 CUSIP: 25056L103 ISIN: US25056L1035 LEI: - UEI: -
Secondary Listings
DSGN has no secondary listings inside our databases.